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ABSTRACT Increasing sterile syringe access for injection drug users (IDUs) is one way to
prevent HIV and hepatitis C virus (HCV) transmission in this population. In 2005,
California Senate Bill 1159 allowed counties to adopt the Disease Prevention
Demonstration Project (DPDP). Where enacted, the DPDP allows pharmacies that
register with the county to sell up to ten syringes to adults without a prescription. In the
current study, we describe pharmacy participation in nonprescription syringe sales
(NPSS) in two counties in California and examine factors associated with NPSS.
Telephone and in-person interviews were conducted in Los Angeles (LA) and San
Francisco (SF) with 238 pharmacies in 2007 (n = 67 in SF; n = 171 in LA). Quantitative
survey items captured pharmacy registration with the county, pharmacy policies/
practices, episodes and conditions of NPSS and refusals to sell, potential negative
consequences of NPSS, and staff attitudes regarding HIV and HCV prevention for
IDUs. Overall, 42% of pharmacies reported NPSS (28% in LA and 81% in SF),
although only 34% had registered with the county (17% in LA and 76% in SF). Many
pharmacies required proof of a medical condition (80% in LA and 30% in SF) and
refused NPSS if the customer was a suspected IDU (74% in LA, 33% in SF). Few
negative consequences of NPSS were reported. In multivariate logistic regression
analysis, we found that the odds of NPSS were significantly higher among pharmacists
who thought syringe access was important for preventing HIV among IDUs [adjusted
odds ratio (AOR) = 2.95; 95% confidence interval (CI) = 1.10–7.92], were chain
pharmacies (AOR = 12.5; 95% CI = 4.55–33.33), and were located in SF (AOR = 4.88;
95% CI = 1.94–12.28). These results suggest that NPSS were influenced by
pharmacists’ perception. NPSS might be increased through greater educational efforts
directed at pharmacists, particularly those in non-chain pharmacies.
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543INTRODUCTION
Illicit drug injection accounts for a signiﬁcant proportion of HIV/AIDS cases and the
majority of hepatitis C virus (HCV) cases in the USA.
1,2 To prevent the spread of
HIV and HCV, federal ofﬁcials have recommended that injection drug users (IDUs)
inject with a clean, unused syringe each time they use.
3–5 To achieve this
recommendation, IDUs must have access to clean syringes. In the USA, clean
syringes can be obtained through nonprescription syringe sales (NPSS) at
pharmacies or through syringe exchange programs (SEPs).
Avariety of studies indicate that pharmacy access to sterile syringes could have a
signiﬁcant impact on efforts to prevent HIV and HCV among IDUs.
6,7 While the
entire USA had G200 SEPs in 2005,
8 California had over 7,000 licensed pharmacies
in 2007, but only 17 SEP sites in San Francisco and 24 in Los Angeles. In addition,
as compared to SEPs, pharmacies are neither politically controversial nor do they
require funding from government and/or foundations to operate.
9,10 Lastly,
pharmacy access to syringes has been shown to be effective at lowering injection-
related HIV risk behaviors among the IDUs who use them.
11–13
However, not all pharmacies are willing to conduct NPSS. Rural pharmacists in
Connecticut, Missouri, Kentucky, and Colorado were less supportive of NPSS than
their urban counterparts.
14 Chain pharmacies have been found to be more likely to
sell syringes than independent pharmacies.
12,15,16 Furthermore, pharmacy managers
and supervisors as well as pharmacists with ten or more years of experience have
been found to be more likely to support NPSS.
15 Lastly, pharmacists who viewed
drug use and addiction as public health issues were more likely to support NPSS
than those who regarded addiction as a personal choice.
17,18 These studies
underscore that permitting NPSS does not guarantee pharmacy participation.
However, pharmacy participation in NPSS is critical if this method of sterile syringe
access is to have its intended impact on preventing HIV and HCV infection among
IDUs.
An additional impediment to pharmacy syringe sales is medical prescription
laws that prohibit pharmacies from selling syringes to adults without a doctor’s
prescription. California is one of only a few states that have a medical prescription
law for syringes. In 2005, the state legislature and governor enacted Senate Bill (SB)
1159 to amend this law through the establishment of Disease Prevention
Demonstration Projects (DPDP). For county and city governments that opt-in to
the DPDP, pharmacies that register with the local government can sell up to ten
syringes to adults (18 years of age or older) without a medical prescription. In
addition, local governments can require pharmacies that participate in the DPDP to
provide information on syringe disposal, drug treatment, infectious disease testing,
and other medical and social services. Lastly, in DPDP locales, adults may legally
possess up to ten syringes without a prescription provided that these syringes were
obtained from an authorized source (i.e., registered pharmacy or legal SEP). More
details on the DPDP are available elsewhere.
19
As we have noted, variability in pharmacy participation should be expected. In
this paper, we examine DPDP implementation in two large and important counties
in California—Los Angeles (LA) and San Francisco (SF). While limited funding and
logistical concerns inﬂuenced the selection of these two counties, it is also worth
noting that SF can be classiﬁed as an early adopter of syringe access and other health
interventions for IDUs. In SF, SEPs were implemented in 1989, the DPDP was
adopted in 2005, and Naloxone distribution for the reversal of heroin overdoses
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until 1995, the DPDP was not adopted until early 2007, and county-approved
Naloxone distribution did not start until 2007. In the following, we will present data
describing differences in NPSS uptake and practices in LA and SF.
We were also interested in a number of other issues including whether
implementationofNPSSwasassociatedwithanyunintendedornegativeconsequences.
And lastly, we conducted analyses to determine what factors (including city, pharmacy
characteristics,andpharmacists’ attitudesand beliefs) wereassociatedwithNPSSinthe
overall sample of pharmacies in our study.
METHODS
Data for this study came from quantitative surveys conducted with pharmacies in SF
and LA Counties. Licensed pharmacies as of February 1, 2007 were identiﬁed from
a list obtained from the California Board of Pharmacy. Surveys were restricted to
retail pharmacies, thus excluding those that were not open to the general public. All
retail pharmacies in SF (N = 132) were originally included in the sample. However,
during recruitment, we discovered that 27 pharmacies had closed, moved without
providing forwarding information, or discontinued the pharmacy component of
their business, leaving our overall sample size for SF at 106. Since LA County had
over 1,700 retail pharmacies in 2007 and we lacked the resources to contact and
interview all of them, we restricted our LA sample in the following ways. First, we
selected three special planning areas (SPAs) in LA County that had the highest rates
of injection-related HIV/AIDS.
20 Within these three SPAs (4, 6, and 8), using data
from the LA Alcohol and Drug Program, we calculated the total number of IDUs in
treatment and average number of IDUs in treatment for each zip code from 2004 to
2006. Zip codes with both above average counts of IDUs and above average IDUs in
treatment per capita were identiﬁed (N = 100). From this list, 33 zip codes were
selected with the highest counts and average. In these zip codes, 211 pharmacies
were listed and efforts were made to recruit all eligible pharmacies.
Each selected pharmacy was sent an informational letter and received a follow-up
call1weeklater, duringwhichthe phone interviewer askedtospeak withthe pharmacy
manager or another person who was knowledgeable about pharmacy practices (e.g.,
pharmacytechnicians).Variousmethodswereusedtoimproveresponserates,including
in-personinterviewsinLAandmailedandfaxedsurveys(inbothlocations).Usingthese
methods, 67 (or 64% of total) surveys were completed in SF and 171 (or 81% of total)
were completed in LA, for an overall response rate of 75%.
After completing verbal informed consent, pharmacists were asked a series of
questions about their participation in the local DPDP, including registration and
syringe sales; conditions of syringe sales; any refusals of sales and the reasons for it;
knowledge, attitudes, and beliefs about syringe access; and any perceived problems
related to NPSS. For completing the survey, pharmacists received a $10 bookstore
gift card. All study procedures were reviewed and approved by the Institutional
Review Board at California State University Dominguez Hills and the Committee for
the Protection of Human Subjects, Health and Human Services Agency, State of
California.
Study Measures
Pharmacies were designated as registered or not registered to sell syringes with their
local DPDP as well as whether they had actually sold syringes without a prescription
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information on drug treatment, HIV, and HCV testing, syringe disposal, and needle
exchange was assessed among pharmacies that reported NPSS, as was the frequency
of NPSS during January 2007 and the estimated proportion of NPSS purchasers
who were IDUs. The survey also assessed syringe disposal options, requirements for
syringe sales, and syringe sale refusals. Pharmacists were also asked if they placed
conditions on NPSS beyond verifying the age of customers.
Questions regarding potential unintended or negative consequences of NPSS
were asked, including the frequency of problems (many, some, few, or no problems)
and whether the following incidents had occurred related to nonprescription
pharmacy sales: underage person attempting to buy syringes, verbal or other abuse
by persons, increase in the amount of used syringes found on premises, increase in
the amount of injection drug use on the premises, increase in shoplifting or other
thefts, customer complaints, community opposition, and increase in condom sales.
To identify factors associated with NPSS, we assessed pharmacists’ attitudes
toward NPSS as well as pharmacy type [chain, independent, care (i.e., Kaiser or
community clinic-based facility)], location (free standing, mall or shopping center, in
hospital or clinic, in grocery store), and county (LA vs. SF). For attitudes, we used a
Likert scale (strongly agree, agree, not sure, disagree, strongly disagree) to assess
endorsement of the following items: “Injection drug users will continue to share
syringes at the same rate even if they have increased access to clean syringes;”“ It is
important to provide clean syringes to people who cannot stop injecting drugs;”
“Pharmacy access to syringes is an important public health measure;”“ An increase
in syringe access will increase the number of syringes found on the street and on
playgrounds;”“ HIV/AIDS is an important health concern in the area served by my
pharmacy;” and “Hepatitis C virus infection is an important concern in the area
served by my pharmacy.” To facilitate analysis, we recoded these response items to
agree which includes strongly agree and agree vs. all other responses (not sure,
disagree, strongly disagree).
Statistical Analysis
Frequencies and proportions were used to describe the sample population and
central tendencies. Chi-square and Fisher’s exact test indicated signiﬁcant bivariate
associations between pharmacy participation and practices related to NPSS. To
determine factors independently associated with reporting at least one NPSS in the
last 12 months, we conducted multivariate logistic regression with pharmacists’
attitudes and characteristics (i.e., years at the pharmacy), pharmacy characteristics
(including type—chain, independent, or care), and county as potential predictors. In
this model, we included factors found to be signiﬁcant in bivariate analysis at the pG
0.05 level. We also reran multivariate logistic regression for NPSS participation and
enrollment in DPDP separately for each site.
RESULTS
Two-hundred thirty-eight surveys were completed (67 in SF and 171 in LA). Overall,
52% of pharmacies were chain stores, 43% were independents, and 5% were care
pharmacies. In terms of location, 45% were free-standing retail pharmacies, 20%
were inside a grocery store, 20% were inside a mall, and 15% were located in a
hospital or clinic.
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reported being registered with the county as required by the DPDP. However, a total
of 42% of pharmacies reported NPSS in the last 12 months (28% in LA and 81% in
SF), suggesting that some pharmacies sold without being registered. Based on
estimates provided by respondents, in January 2007, a total of 13,715 syringes
(range 10–7,100) were sold in SF and 4,490 (range 10–1,000) were sold in LA. The
estimated proportion of IDUs among syringe buying customers was 66% in SF and
16% in LA (pG0.001). Due to the consistent differences by county in pharmacy
participation, we present the remaining data on pharmacy participation by county.
Information provided (i.e., pamphlets) and syringe disposal options offered by
pharmacists that conducted NPSS in the last 12 months differed by county (Table 1).
A higher proportion of pharmacies in SF offered information about syringe disposal
(54% in LA and 91% in SF) and SEPs (28% in LA and 76% in SF) compared to
those in LA. In terms of syringe disposal, a higher proportion of SF pharmacies
provided free sharps containers (11% in LA and 76% in SF), on-site syringe drop
box (9% in LA and 46% in SF), and acceptance of personal sharps containers (13%
in LA and 73% in SF). A higher proportion of LA pharmacies offered sharps
containers for purchase (76% in LA and 38% in SF). No county differences were
observed in the availability of mail-back sharps containers, providing counseling on
syringe disposal, and referring customers to other syringe disposal locales.
Table 2 presents data on the type of requirements pharmacies used before
conducting a NPSS. The most prevalent requirement was proof of medical condition
(80% in LA and 30% in SF), followed by logging customer name (70% in LA and
22% in SF). In all cases, requirements were used more frequently in LA.
We also assessed whether NPSS requests were refused and the reasons for the
refusal. Overall, 39% reported never refusing, 36% reported rarely refusing, and
25% reported sometimes or often refusing. County differences were noted, however,
with 87% of SF pharmacies reporting never or rarely refusing to sell syringes, while
TABLE 1 Information and syringe disposal options provided by pharmacies that sold syringes
without a prescription during the past 12 months in Los Angeles and San Francisco, January
2007 (n = 101)
Los Angeles (n = 47) San Francisco(n = 54)
Information given
Drug treatment (%) 39 56
HIV/HCV prevention and testing (%) 34 47
Syringe exchange program* (%) 28 76
Syringe disposal* (%) 54 91
Syringe disposal options
Free sharps containers* (%) 11 76
Drop box* (%) 9 46
Sharps containers for sale* (%) 76 38
Mail-back containers (%) 20 24
Accepts sharps containers* (%) 13 73
Accepts loose syringes (%) 11 15
Literature on syringe disposal options* (%) 22 64
Counseling on syringe disposal (%) 56 67
Referral to other locations for disposal (%) 47 33
*pG0.001
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reported sometimes refusing to sell syringes.
Table 2 also reports reasons cited by pharmacies for not selling syringes.
Differences by county were found for all reasons, with LA pharmacies more likely to
endorse every reason for refusing than their SF counterparts. The most common
reasons for refusing NPSS in LAwas customer intoxication followed by known IDU
and safety concerns, while in SF, the most frequently endorsed item was safety
concerns, followed by intoxication. SF pharmacists also endorsed excessive
purchases and risk of theft as reasons for not selling syringes.
We also explored how pharmacist’s knowledge, attitudes and beliefs, pharmacy
type, and pharmacy location might inﬂuence NPSS decisions. Pharmacists who
thought NPSS would be effective, that syringe access was important for HIV
prevention, and that HIV is a problem in their area were signiﬁcantly more likely to
have sold syringes (Table 3). Chain pharmacies and those located in grocery stores
were more likely to report NPSS as compared to pharmacies in care settings. In
multivariate analysis, we found that endorsement of syringe access was important
for HIV prevention [adjusted odds ratio (AOR) = 2.95, 95% conﬁdence interval
(CI) = 1.10–7.92], chain pharmacy (AOR = 12.5; 95% CI = 4.55–33.33), and being
in SF (AOR = 4.88; 95% CI = 1.94–12.28) were independently associated with
providing NPSS. DPDP registration was not signiﬁcantly associated with NPSS in
the last 12 months.
Due to the consistent differences by county, we constructed models of NPSS for
each site. In Los Angeles, we found both endorsement of syringe access as being
important for HIV prevention (p = 0.042) and chain pharmacy (pG0.001 as
compared to independent pharmacy) as statistically signiﬁcant predictors of NPSS.
In SF, only chain pharmacy (pG0.001) predicted NPSS.
Lastly, we looked at reported problems related to NPSS. Roughly 60% of
pharmacists reported no problems at all. In addition, the problem cited most
(∼25%) in both LA and SF was verbal abuse by buyers. Approximately 15% of
pharmacists also reported theft in the store as a problem. Levels of criminal activity
TABLE 2 Conditions for nonprescription syringe sales in LA and SF, 2007 (n = 101).
Los Angeles (n = 47) San Francisco (n = 54)
Requirements
Medical condition** (%) 80 30
Picture identiﬁcation** (%) 54 19
Customer name** (%) 63 17
Justiﬁcation* (%) 39 13
Log customers** (%) 70 22
Reasons for refusals
Unfamiliar customer** (%) 65 11
Known IDU** (%) 72 11
Disheveled appearance** (%) 35 4
Intoxication** (%) 78 32
Excessive purchases* (%) 46 26
Safety concerns* (%) 67 43
Concerns about unsafe disposal* (%) 46 19
Risk of theft* (%) 46 26
*pG0.05; **pG0.001
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signiﬁcantly based on pharmacies reports.
DISCUSSION
Two years after the implementation of SB1159, substantial differences were
observed in the implementation of NPSS in LA and SF. SF pharmacies were more
likely to conduct NPSS and less likely to impose requirements on NPSS than their
LA counterparts. These differences may be explained by a number of factors
including the earlier start of DPDP in SF (2005 as compared to 2007 in LA), higher
per capita HIV rates in SF as compared to LA, and/or differences in political
attitudes and priorities. This study, and others like it, indicates that detailed research
on adoption of NPSS among pharmacies is needed to determine how to improve
pharmacy participation in these important public health strategies.
We also found that within NPSS, a number of operational barriers are apparent.
In LA, the current level of implementation (G30% of pharmacies participate) and the
reports of NPSS refusals suggest that syringe access through pharmacies could be
increased. With time, this may occur, as has occurred in SF. Given that pharmacists’
attitudes were related to NPSS participation, one way to increase pharmacy
participation might be through educational programs. Other investigators have
recommended pharmacist education as one way to increase participation in
NPSS.
18,21,22 In fact, at least one study has found that efforts to inform community
members and pharmacists about the importance of sterile syringe access appeared to
TABLE 3 Bivariate analysis of factors signiﬁcantly associated with one or more non-
prescription syringe sales during the past year in LA and SF, 2007 (n = 238)
No sales (n = 137) Sales (n = 101)
Pharmacists’ attitudes and belief
IDUs will continue to share syringes at the same rate
even if they have increased access to clean syringes—
agree* (%)
43 30
It is important to provide clean syringes to people who
cannot stop injecting drugs—agree* (%)
68 86
Pharmacy access to syringes is an important public
health measure—agree* (%)
83 93
An increase in syringe access will increase the number
of syringes found on the street and on playgrounds—
agree* (%)
55 37
HIV/AIDS is an important health concern in the area
served by my pharmacy—agree* (%)
72 83
Pharmacy type
Chain (n = 120)** (%) 32 68
Independent (n = 99) (%) 87 13
Care (n = 10) (%) 90 10
Pharmacy setting
In grocery—Yes* (%) 40 60
No (%) 62 38
In hospital or clinic—Yes** (%) 85 15
No (%) 53 47
*pG0.05; **pG0.001
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12 Such
efforts should be considered in areas where pharmacy participation rates appear
low.
Another important implication of this research regards the potential negative
consequences of this policy. As in other studies,
23 most pharmacists reported no
problems related to NPSS, although evaluation of more objective information such
as police calls and arrests could further elucidate these issues. As part of our overall
efforts to study the potential negative impacts of this policy, we have also collected
data from pharmacists in 2008 as well as conducted physical observations of streets
around pharmacies. We will present the results of these data in subsequent reports.
These study results should be considered in light of the following limitations.
Interviews were completed with a variety of pharmacy personnel (i.e., managers,
technicians), some of whom may not have had complete information on relevant
pharmacy policies or practices. However, it is worth noting that rates of
participation in NPSS in SF are similar to those found in another survey using
mailed questionnaires.
24 In terms of our attitude items, these were asked of
individuals and may not reﬂect the overall attitudes of other professional staff in a
pharmacy. As with all self-reported data, there are concerns regarding socially
desirable responding and recall bias. For some items, we also asked pharmacists to
estimate activities such as syringes sold or frequency of refusing to sell syringes; in
those cases, it is impossible to know the accuracy of these estimates.
There are a number of issues related to sampling and response rates that should
also be considered. Our sampling frames and recruitment methods differed by
county due to resources and geographic proximity. The large number of pharmacies
in LA County (∼1,700) prevented us from attempting to contact them all, and so the
LA sample should not be considered representative of all pharmacies in LA County.
Furthermore, in LA, we focused on a subsample of pharmacies in high-need areas.
This difference in sampling frame may have inﬂuenced our outcomes. Some studies
have found that pharmacies in high need areas (i.e., elevated IDU and HIV rates)
were more likely to participate in NPSS than those in lower need areas.
25 So our site
comparison may well be overestimating LA pharmacy participation in NPSS.
Lastly, because of geographic proximity, we were able to also conduct in-person
recruitment and interviews at pharmacies in LA. This contributed to our differential
response rates (63% in SF vs. 81% in LA). We conducted two additional analyses to
account for this difference. First, to determine if site differences in NPSS
participation were due to response rates differences, we recalculated NPSS
participation for SF, assuming it had the same response rates as LA (81%) and
that all non-responders reported not participating in NPSS (the most conservative
assumption). In this analysis, we found that the NPSS participation rate in SF would
be 59% (54/86) and that as compared to LA (28%), this difference would still be
signiﬁcant (pG0.0001) using Pearson chi-square test. Second, we reran the
multivariate logistic regression predicting NPSS participation separately by site. In
LA, we found that both endorsement of the importance of syringe access and chain
pharmacy predicted NPSS participation, while in SF, only pharmacy type
signiﬁcantly predicted NPSS participation. However, it is worth noting that we did
not have any care pharmacies in our SF site and that the point estimate of the
importance of syringe access was in the predictive direction in SF as well. The
smaller sample size in SF also impacted this reanalysis. We conclude that chain
pharmacy involvement has been key in expanding NPSS and that pharmacists’
attitudes in LA are an important contributor to NPSS involvement. Why chain
COOPER ET AL. 550pharmacy participation rates are higher was not an issue we could address given our
methods and resources.
Substantial legal and policy changes to prevent HIVand hepatitis C virus infection
among IDUs have been made in the last decade. However, as laws and policies are
changed to promote infectious disease prevention for IDUs, attention must be paid to
the implementation of these policy changes, particularly for NPSS where adoption has
been found to vary inversely with need in a few cases.
22,26 Our results indicate that
there were substantial differences in the adoption of NPSS in our two study sites.
More studies that examine the process and outcome evaluations of policy changes are
needed, as are studies of potential negative consequences of these changes. In addition,
to maximize the impact of this policy change, additional efforts appear needed to
increase local acceptability, thus broadening implementation among and within
counties. In LA and SF, NPSS might be increased through greater educational efforts
directed at pharmacists, particularly those who work in independent pharmacies.
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